Vice President, Analytical Development & Quality Control
Revolution Medicines - Redwood City, California, United States
Posted Apr 10, 2026
Benefits
- Parental leave
- Not verified
- Non-birth-parent leave
- Not verified
- Family-building benefits
-
- Fertility benefits: Not verified
- Adoption assistance: Not verified
- Surrogacy assistance: Not verified
- Mental health support
- Not verified
- Relocation assistance
- Not verified
- Childcare support
- Not verified
- Learning budget
- Not verified
- Verification
- Not verified
- Salary
- Not verified not verified - source not recorded; timestamp not recorded
- 401(k) match
- Not verified
Was this benefit information wrong? Tell us.
Market context
- Median wage (BLS OEWS)
- $116,543 national median
- Projected growth (BLS Employment Projections)
- +9.8% - Much faster than average
184% above the BLS national median for software engineering aggregate.
Matched to SOC 15-1252 - Software Engineering aggregate by role bucket.
Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.
Schedule
- Shift type
- Not verified
- Weekend work
- Not verified
Application
- Cover letter
- Not verified
- Assessment
- Not verified
- Deadline
- Not stated
Where they hire
State eligibility is not yet verified.
About this role
Vice President, Analytical Development & Quality Control Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a strategic and execution-driven Vice President, Analytical Development & Quality Control (ADQC) to lead the vision, strategy, and execution of analytical development and QC across our growing portfolio. Reporting to the Senior Vice President, Pharmaceutical Development & Manufacturing, this executive will build and scale a phase-appropriate, forward-looking analytical organization that enables rapid development of small molecule programs while positioning the company for late-stage development and global commercialization. As a key member of the PDM leadership team, this role will shape analytical strategy at the enterprise level, ensuring robust control strategies, regulatory readiness, and operational excellence across internal and external networks. Responsibilities: Strategic & Organizational Leadership - Define and drive the enterprise-wide analytical development and QC strategy aligned with portfolio and corporate objectives. - Build, lead, and scale a high-performing ADQC organization to support a multi-asset oncology pipeline.
Read the full description at www.revmed.com. FewerJobs shows a source-linked preview and links to the original posting.
Apply link not verified; last-live date unavailable.
What verified means
Verified means a displayed claim has a recorded source field, a source URL when available, and a timestamp showing when FewerJobs checked or enriched the evidence.
Related jobs
-
Director of Product, Core Remittance Experience
Remitly Global INC - Seattle, Washington United States
-
Product Security Principal
Flagstar BANK National Association - 2 Locations
-
Staff Software IPT Lead
Northrop Grumman - United States-California-Woodland Hills
-
Director of Financial Planning & Practice Development
UMB Financial CORP - Leawood KS